• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Maravai LifeSciences Holdings Inc. (Amendment)

    2/28/24 4:15:24 PM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRVI alert in real time by email
    SC 13G/A 1 p24-1054sc13ga.htm MARAVAI LIFESCIENCES HOLDINGS, INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     

    Maravai LifeSciences Holdings, Inc.

    (Name of Issuer)
     

    Class A Common Stock, par value $0.01 per share

    (Title of Class of Securities)
     

    56600D107

    (CUSIP Number)
     

    December 31, 2023**

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    **This Schedule 13G/A amends and restates the Schedule 13G filed by the Reporting Persons on February 14, 2024 in its entirety.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 56600D107

    13G/APage 2 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

     

    12 West Capital Management LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    11,602,988

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    11,602,988

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    11,602,988

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.8%

    12

    TYPE OF REPORTING PERSON

    PN, IA

             

     

     

     

     

    CUSIP No. 56600D107

    13G/APage 3 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Joel Ramin

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    11,602,988

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    11,602,988

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    11,602,988

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.8%

    12

    TYPE OF REPORTING PERSON

    IN, HC

             

     

     

     

    CUSIP No. 56600D107

    13G/APage 4 of 7 Pages

     

    Item 1(a). Name of Issuer.
       
      The name of the Issuer is Maravai LifeSciences Holdings, Inc. (the “Company”).

     

    Item 1(b). Address of Issuer's Principal Executive Offices.
       
      The Company’s principal executive offices are located at 10770 Wateridge Circle, Suite 200, San Diego, CA 92121.

     

    Item 2(a). Name of Person Filing.
       
      This statement is filed by:  

     

      (i) 12 West Capital Management LP (“12 West Management”), a Delaware limited partnership,  and the investment manager to 12 West Capital Fund LP, a Delaware limited partnership and 12 West Capital Offshore Fund LP, a Cayman Islands exempted limited partnership (“12 West Funds”), with respect to the shares of Class A Common Stock (as defined in Item 2(d) below) directly held by the 12 West Funds; and
         
      (ii) Mr. Joel Ramin (“Mr. Ramin”), the sole member of 12 West Capital Management, LLC (“12 West LLC”), the general partner of 12 West Management, with respect to the shares of Class A Common Stock directly held by the 12 West Funds.
       
      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
       
      The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Class A Common Stock reported herein.  

     

    Item 2(b). Address of Principal Business Office.
       
      The address of the principal business office of each of the Reporting Persons is 475 Tenth Avenue, 14th Floor, New York, NY 10018.
       
    Item 2(c). Place of Organization.
       
      12 West Management is a Delaware limited partnership. Mr. Ramin is a United States citizen.

     

    Item 2(d). Title of Class of Securities.
       
      Class A common stock, par value $0.01 per share (the “ Class A Common Stock”)

     

    Item 2(e). CUSIP Number.
       
      56600D107

     

     

     

    CUSIP No. 56600D107

    13G/APage 5 of 7 Pages

     

    Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:

     

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) x An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

      (g) x

    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K).
     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:__________________________________________

     

    Item 4. Ownership.
       
     

    The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for the Reporting Person hereto and is incorporated herein by reference for the Reporting Person.

     

    The percentages set forth herein are calculated based upon 132,188,632 shares of Class A Common Stock outstanding as of November 1, 2023, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ending September 30, 2023, filed with the Securities and Exchange Commission on November 8, 2023.

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      Not applicable.

     

     

     

    CUSIP No. 56600D107

    13G/APage 6 of 7 Pages

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      See Item 2(a). The 12 West Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Class A Common Stock reported herein. 12 West Capital Fund LP, a 12 West Fund, has the right to receive or the power to direct the receipt of dividends or the proceeds from the sale of more than 5% of the shares of Class A Common Stock.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
      Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.
       
      Not applicable.

     

    Item 9. Notice of Dissolution of Group.
       
      Not applicable.

     

    Item 10. Certification.
       
      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No. 56600D107

    13G/APage 7 of 7 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date:  February 28, 2024  
      12 WEST CAPITAL MANAGEMENT LP
      By: 12 West Capital Management, LLC, its General Partner
       
      By:

    /s/ Joel Ramin

      Name: Joel Ramin
      Title: Sole Member
       
     

    /s/ Joel Ramin

      Joel Ramin

     

    .

     

     

     

    Get the next $MRVI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MRVI

    DatePrice TargetRatingAnalyst
    2/26/2025$9.00 → $3.00Outperform → Neutral
    Robert W. Baird
    12/19/2024Neutral
    Guggenheim
    12/5/2024$4.25Neutral → Sell
    Goldman
    11/14/2024Peer Perform
    Wolfe Research
    11/8/2024Outperform → Mkt Perform
    William Blair
    8/28/2024$10.00Overweight
    Wells Fargo
    8/13/2024$11.00 → $10.00Overweight → Equal-Weight
    Morgan Stanley
    4/10/2024$15.00Buy
    Craig Hallum
    More analyst ratings

    $MRVI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer and Member of its Board of Directors

      SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the appointment of Bernd Brust as Chief Executive Officer (CEO) and a member of the Board of Directors, effective immediately. Mr. Brust succeeds William "Trey" Martin III in these roles. "This leadership transition reflects Maravai's commitment to accelerating innovation, execution, and financial performance. Bernd brings more than 30 years of leadership experience in the life sciences industry, with a proven track record of transforming businesses into profitable, revenue-growing com

      6/9/25 8:30:00 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TriLink BioTechnologies® and Quantoom Biosciences Sign License and Supply Agreement for CleanCap® mRNA Capping Technology

      Quantoom's customers can now access TriLink's CleanCap mRNA capping technology; Agreement supports future expansion of essential therapeutics & vaccines in developing countries & regions TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ:MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Quantoom Biosciences, a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics. Under the agreement, Quantoom will have access to TriLink's CleanCap® mRNA capping technology for integration in its Ntensify® (sa)mRNA production platform to help accelerate the RNA production process and ma

      6/3/25 10:00:00 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report

      Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- This release corrects and replaces the version distributed earlier today at 16:05 ET. The original version included the incorrect title of "Maravai LifeSciencesReleases 2024 Sustainability Report". The corrected title is "Maravai LifeSciences Releases 2024 Sustainability Report". Maravai Lif

      5/21/25 4:22:17 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRVI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maravai Life Sciences downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Maravai Life Sciences from Outperform to Neutral and set a new price target of $3.00 from $9.00 previously

      2/26/25 7:15:06 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Maravai Life Sciences

      Guggenheim initiated coverage of Maravai Life Sciences with a rating of Neutral

      12/19/24 8:13:54 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maravai Life Sciences downgraded by Goldman with a new price target

      Goldman downgraded Maravai Life Sciences from Neutral to Sell and set a new price target of $4.25

      12/5/24 7:46:04 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRVI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Deford John A bought $100,625 worth of shares (17,500 units at $5.75), increasing direct ownership by 33% to 70,046 units (SEC Form 4)

      4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)

      11/14/24 4:32:08 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Hull Carl bought $987,000 worth of shares (175,000 units at $5.64) (SEC Form 4)

      4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)

      11/12/24 4:59:43 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRVI
    SEC Filings

    See more
    • Maravai LifeSciences Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Filer)

      6/9/25 8:40:50 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Maravai LifeSciences Holdings Inc.

      SCHEDULE 13G - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)

      5/29/25 5:24:04 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maravai LifeSciences Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Filer)

      5/28/25 5:26:08 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRVI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Marker Luke Joseph was granted 89,139 shares, increasing direct ownership by 182% to 138,055 units (SEC Form 4)

      4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)

      6/18/25 6:25:09 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Gray Susannah was granted 89,139 shares, increasing direct ownership by 110% to 169,907 units (SEC Form 4)

      4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)

      6/18/25 6:25:19 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Daverman Benjamin James was granted 89,139 shares, increasing direct ownership by 182% to 138,055 units (SEC Form 4)

      4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)

      6/18/25 6:25:28 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRVI
    Leadership Updates

    Live Leadership Updates

    See more
    • Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer and Member of its Board of Directors

      SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the appointment of Bernd Brust as Chief Executive Officer (CEO) and a member of the Board of Directors, effective immediately. Mr. Brust succeeds William "Trey" Martin III in these roles. "This leadership transition reflects Maravai's commitment to accelerating innovation, execution, and financial performance. Bernd brings more than 30 years of leadership experience in the life sciences industry, with a proven track record of transforming businesses into profitable, revenue-growing com

      6/9/25 8:30:00 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report

      Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- This release corrects and replaces the version distributed earlier today at 16:05 ET. The original version included the incorrect title of "Maravai LifeSciencesReleases 2024 Sustainability Report". The corrected title is "Maravai LifeSciences Releases 2024 Sustainability Report". Maravai Lif

      5/21/25 4:22:17 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maravai LifeSciencesReleases 2024 Sustainability Report

      Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of lifescience reagents and services to researchers and biotech innovators through its portfolio companies TriLink BioTechnologies, Glen Research, Alphazyme, and Cygnus Technologies, today announced the publication of its 2

      5/21/25 4:05:00 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRVI
    Financials

    Live finance-specific insights

    See more
    • Maravai Lifesciences Reports First Quarter 2025 Financial Results

      SAN DIEGO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2025, together with other business updates. Financial Highlights: Quarterly revenue of $46.9 million, Net loss of $(52.9) million (including a goodwill impairment of $12.4 million), and Adjusted EBITDA of $(10.5) million; andRevenue for the full year 2025 is expected to be in the range of $185.0 million to $205.0 million, unchanged from previous guidance. "Our first quarter revenue exceeded our guidance range, an

      5/12/25 4:06:17 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maravai LifeSciences To Host Earnings Conference Call on Monday, May 12, 2025

      SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2025 financial and operating results after the market close on Monday, May 12, 2025, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial (800) 343-4849 or (203) 518-9848 and reference Maravai LifeSciences, Conference ID MARAVAI. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.maravai.com.

      5/1/25 7:30:00 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maravai Lifesciences Reports Fourth Quarter and Full Year 2024 Financial Results

      SAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and full year ended December 31, 2024, together with other business updates. The company also expects to file its Annual Report on Form 10-K for the year ended December 31, 2024, with the Securities and Exchange Commission today. Upon filing, a copy of the annual report will be available on Maravai's website, www.maravai.com, by selecting "Investors" and then "SEC Filings." Key Financial Results: Quarterly revenue of $56.6 million, Ne

      3/18/25 4:05:56 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRVI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Maravai LifeSciences Holdings Inc.

      SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)

      11/14/24 7:49:19 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Maravai LifeSciences Holdings Inc.

      SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)

      11/13/24 4:48:49 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Maravai LifeSciences Holdings Inc.

      SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)

      11/13/24 9:30:19 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care